In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vical Inc.

www.vical.com

Latest From Vical Inc.

Interview: ViroMed On Pricing, Manufacturing World’s First Broadly Used Gene Therapy

The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.

South Korea Pricing Strategies

Finance Watch: Anchiano, TCR2, Hoth And Stealth Make Seven US Biopharma IPOs For 2019

Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.

Financing Business Strategies

Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta

Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.

M & A Deals

Pipeline Watch Phase III Progress With Trintellix, Ocrevus And Olumiant

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vical Inc.
  • Senior Management
  • Vijay B Samant, Pres. & CEO
    Keith D Hall, VP, Ops
    Mammen Jr. Mammen, MD, VP, Clinical Vaccines
    Larry Smith, PhD, VP, Vaccine Research
    Anthony Ramos, VP Finance, CAO
  • Contact Info
  • Vical Inc.
    Phone: (858) 646-1100
    10390 Pacific Center Ct.
    San Diego, CA 92121-4340
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register